Vaccines based on ITGB4-expressing dendritic cells (mITGB4-DC) or adoptive transfer of BiAb-armed T cells targeting ITGB4 have been shown to suppress both CSCs and bulk tumor cells in preclinical models, reducing local tumor growth and metastasis [22]. The gene discussed is ITGB4; the disease is neoplasm.